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WHAT IS WRONG WITH MY 
PATIENT? HOW TO READ AN 
ARTICLE CONCERNING 
DIAGNOSIS 
P Rheeder, J A Ker 
Two critically important questions arise from the doctor-patient 
encounter. Firstly, given the patient's profile (demography, 
signs and symptoms), what is the most likely diagnosis, and 
secondly given the diagnosis what is the most effective 
intervention? 
Diagnostic reasoning skills are vital for effective patient care. 
The basis of these skills should be sound diagnostic research on 
the appropriate signs, symptoms and tests regarding a 
particular disease. Diagnostic research has undergone 
significant developments during the last number of years. 
Some of these principles are common knowledge while others 
are poorly understood. Given that diagnostic knowledge is 
vital for patient care it is imperative that the practising 
physician should be able to appraise articles on diagnostic 
research critically. 
The development of diagnostic research has been a stepwise 
refinement of concepts (Fig.1). 
Prediction rules Sensitivity and specificity 
t 
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Fig. 1. Progressive steps in diagnostic research. 
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The sensitivity of a test is typically given as (a/(a + c)). This 
can be translated into the probability of finding a test positive 
given a certain disease: P(T+ ;o+). Specificity is (d/(d + b) or 
P(r /0-). Reporting the sensitivity and specificity of a test can 
be helpful as a negative Sensitive test rules out disease 
(SNOUT) and a positive Specific test rules in disease (SPIN). 1 
There is always a trade-off between sensitivity and specificity. 
The higher the sensitivity the lower the specificity and vice 
versa (later illustrated with Receiver Operating Characteristic 
(ROC) curves).' 
In principle the diagnostician is not interested to know how 
the test will perform given a diseased or disease-free patient. 
The disease status of the patient is his prime concern and 
therefore the diagnostician is interested in P(D+ /T+) or 
P(o-;r), that is, the probability of disease or not given a 
particular test result. This leads to the concept of positive 
predictive value (PPV) or negative predictive value (NPV). 
Predictive values2 







The PPV P(o+ /T+) is given by (a/a+ b), and the NPV 
co- /T.) by (d/c + d). These values are clearly useful as a PPV 
of, e.g. 80%, will imply that given a positive test result the 
diagnostician can be 80% certain that the patient has the 
disease being tested for. 
However, the value of using predictive values is markedly 
affected by the prevalence of the disease.' Another term often 
used for prevalence is pre-test probability. If the prevalence of 
hypertension in a population of men between the ages of 40 
and 60 years is 20%, then the probability of finding 
hypertension even before you take the blood pressure will be 
20% in a man in that age category. 
Hypothetical example: Test for predicting pancreas 
carcinoma 
o+ o- o+ o- o+ D 
T+ 610 58 436 96 174 150 
T 90 242 64 404 76 650 
Prevalence Prevalence Prevalence 
= 0.7 (70%) = 0.5 (50%) = 0.2 (20%) 
PPV = 0.92 PPV = 0.82 PPV = 0.54 
NPV = 0.73 NPV = 0.86 NPV =0.96 
The PPV will decrease as the prevalence decreases and the 
NPV will increase. The reverse is true when the prevalence 
increases. This is one of the severe limitations of screening 
tests. Screening is usually done in a low-prevalence setting 
with a subsequent low PPV following a positive screening test. 
It should be appreciated that a low PPV implies a high false" 
positive rate. This may lead to unnecessary, expensive, 
sometimes painful or even harmful follow-up testing. 
The following example demonstrates some of these 
principles. A patient presenting with jaundice to a specialised 
liver clinic may have a pre-test probability (given the special 
interest of the clinic) for primary biliary cirrhosis (PBC) as high 
as 40%. A positive serological test may therefore have a high 
PPV for PBC. If, after the liver clinic, one was to see a 
jaundiced patient at the general outpatient clinic, one would 
again order the same serological test. Now the PPV will be 
much less because the prevalence of PBC will be much lower in 
this clinic and the diagnosis of hepatitis A or B much more 
likely. 
Because of the limitation set by the prevalence of the disease, 
a likelihood ratio (LR) might be a better parameter than 
predictive values. 
Likelihood ratio2 
A potential benefit of the LR is that it is not dependent on the 
prevalence of disease. 
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A positive LR is the likelihood of finding a test positive in 
someone diseased compared with the likelihood of finding a 
test positive in someone without the disease: (a/a+ c)/(b/d + 
b) = (sens/1 - spec). A negative LR is (1 - sens/ spec). 
For example, if a test has a positive LR of 18 it implies that a 
diseased person will be 18 times more likely to have a positive 
test than a person without the disease. 
Even though this may be seen as an improvement, LRs have 
some limitations. An LR cannot be translated into a probability. 
('Mrs Smith I am not certain as to what the exact probability is 
that you have a lung embolus, but I can say that if you did not 
have a lung embolus you would have been 18 times less likely 
to have tested positive with this test!') 
Diagnostic tests are often dichotomised into positive and 
negative. The cut-off is often based at a level at which both the 
sensitivity and specificity are at their highest. The relationship 
between sensitivity and specificity is well illustrated with the 
use of ROC curves (Fig. 2). The area under the curve represents 
the ability of the test to distinguish between diseased and non-
diseased states. The diagonal line yields an area below of 0.50 
(50%), i.e. the test has no better predictive ability than flipping 
a coin. When comparing two diagnostic tests, the test with a 
curve closest to the left upper corner is the better test. The cut-
off nearest to the upper left corner also represents the best 
trade-off between sensitivity and specificity and this point is 
often chosen as a cut-off for dichotomising tests. 
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Fig. 2. Receiver Operating Characteristic ROC curve. 
An important concept in diagnostic research which is often 
used subconsciously by the astute clinician is Bayes theorem -
the post-test odds of having a disease = pre-test odds x the LR 
of the positive test. Remember that odds= (probability /1 -
probability). If the pre-test probability (prevalence) before 
testing is 403, then the odds are (0.4/1 - 0.4) = 0.66. If the LR 
for a positive test is 5, then the post-test odds are 3.3 and this 
translates to a post-test probability of (3.3/1 + 3.3) = 0.77 = 
773. Where we were only 403 sure of the diagnosis before 
testing we are now 773 sure. Depending on the disease this 
probability may be high enough to start treatment, or if 
treatment is potentially harmful and more certainty is required 
another test may be used. These difficult calculations can be 
avoided by using Pagan's nomogram' which can be found at 
http://cebm.jr2.ox.ac. uk/ docs I nomogram.html 
Using this approach it can be appreciated why the good 
clinician does not do a diagnostic test (such as a stress 
electrocardiogram (ECG)) on a 20-year-old female patient with 
atypical chest pain. The pre-tesf probability of ischaemic heart 
disease is so low that the diagnostic test would have to have an 
exceptionally high positive LR(+ LR) to change the pre-test 
probablity from 153 to 803. The same reasoning holds why it 
is illogical to do a stress test on a 65-year-old diabetic 
hypertensive male with typical angina. The pre-test probability 
is already 803 or more and even a negative test won't reduce 
this by much and a positive test would only increase this 
probability marginally (you might want to do a stress test for 
prognostic reasons). 
Another use for LRs is to use different cut-off values for a 
test and to give the LR for each cut-off (Table I). Useful 
comments regarding LRs can be found at http: I I cebm.jr2. 
ox.ac.uk/docs/likerats.html and http://www.med. 
ualberta.ca/ebm/ebm.htm (Table II). An LR greater than 1 
produces a post-test probability which is higher than the pre-
test probability. An LR less than 1 produces a post-test 
probability which is lower than the pre-test probability. When 
the pre-test probability lies between 303 and 70%, test results 
with a very high LR (say, above 10) rule in disease. An LR 
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Table I. Use of likelihood ratios at different cut·off values for 
diagnosing acute pancreatitis 
Use of a novel (hypothetical) marker Likelihood ratio 
> 20 mmol/l +LR 10 
15 - 20 mmol/l +LR 6 
10 - 14.9 mmol/l 
5 - 9.9 mmol/l 
1 - 4.9 mmol/l 
+LR2 
+ LR0.8 
+ LRO. 2 
Table II. How much do likelihood ratios (LRs) change disease 
likelihood ? 
• LRs > 10 or < 0.1 cause large changes in likelihood 
• LRs 5-10 or 0.1 - 0.2 cause moderate changes 
• LRs 2 - 5 or 0.2 - 0.5 cause small changes 
• LRs between 2 and > 0.5 cause little or no change 
• LRs of 1.0 cause no change at all 
below 1 produces a post-test probability less than the pre-test 
probability. A very low LR (say, below 0.1) virtually rules out 
the chance that the patient has the disease. 
The LR assumes that sensitivity and specificity are stable test 
characteristics. However, this is not always the case. Severity of 
disease greatly influences these test characteristics. A useful 
example is visual inspection of abdominal girth for diagnosing 
pregnancy. This would be a very poor test early in pregnancy 
bµt a very good test at 9 months' gestation! This has been 
shown to be the case in many circumstances ranging from 
cancer to deep venous thrombosis."' 
The biggest drawback in the evaluation of diagnostic tests up 
to this point has been that the test has been used singularly to 
rule a disease in or out. This is very seldom the case in clinical 
practice and is probably only done when applying screening 
tests. 
In general the clinician uses demographic characteristics, 
history, physical signs and special investigations to confirm a 
diagnosis. Therefore the most valuable technique for 
appraising diagnostic tests would take this into account. 
Logistic regression and prediction rules6'7 
The astute clinician knows that a disease is never diagnosed 
with 100% certainty. Once a certain threshold of probability is 
passed the patient is either sent home or admitted to the 
intensive care unit! This is very well simulated by a logistic 
regression curve. The probability of disease lies between 0 and 
1 in a non-linear fashion. Logistic regression may seem difficult 
to comprehend but the principles are quite straightforward. 
Leaving the statistical notation aside, the logistic function 
describes the probability that the disease in question is present 
given certain clinical parameters such as a certain age, gender, 
pain characteristic, etc. 
Example 1 - diagnosing a pulmonary embolus 
Probability of a pulmonary embolus = 
1 /1 + e - (a+ bl (age)+ b2 (gender)+ b3 (haemoptysis))' 
where a is the intercept and b the regression coefficient. So given 
a certain age, gender and the absence or presence of 
haemoptysis, we can predict the probability of a pulmonary 
embolus. 
One of the most useful characteristics of logistic regression is 
that eb = odds ratio. For example, from your computer output 
you find that the beta coefficient for age = 0.2. This means that 
for each year increase in age you are e02 = 1.2 times more likely 
to have a pulmonary embolus, or more usefully, for every 
decade increase in age you are e' = 7.4 times more likely to 
have a pulmonary embolus than someone a decade younger. 
With logistic regression (bearing in mind all the various steps 
and assumptions) it is possible to use as much information as 
is available to make the diagnosis. For example, age, gender, 
ethnic group, pulse, temperature, pleuritic pain (yes or no), 
haemoptysis (yes or no), pleural rub (yes or no), abnormal 
chest radiograph (yes or no), abnormal ventilation perfusion 
scan (yes or no). 
What is also often done is to follow the stepwise approach 
the clinician normally takes in his diagnostic reasoning. 
1. Using data obtained from history only, a logistical function 
is derived. Many statistical packages such as Stata• can then 
perform a ROC analysis with an area under the curve estimate 
(Fig. 2). 
2. By adding findings from the clinical examination a new 
model can be estimated and an ROC curve drawn. If the 
clinical examination is useful at all the area under the curve 
will improve with statistical significance. 
3. The same can now be done with the added information 
provided by the special investigations. 
After the final logistic regression model has been obtained 
the coefficients are often changed into scores to make the 
regression function more meaningful as a whole (clinical 
prediction rule). An example is the Framingham cardiovascular 
risk equation• (here the outcome is the risk of ischaemic heart 
disease). 
Example 2 - prediction of bacteraemia (positive 
blood cultures)10 
As an intern it would be useful to know beforehand what the 
probability would be of obtaining a positive blood culture in 
any given patient with fever in the ward (especially after 10 at 
night!). Examples of the variable used to derive the risk score 
are given in Table III. 
From Table IV the intern knows that if the score is less than 3 
there is a 99% probability that blood cultures will come back 
negative (all that's left is to convince his consultant that blood 
cultures are unnecessary!). 
Table III. Certain of the variables used for predicting bacteraemia* 
Beta Odds ratio Score 
Maximum 
temperature > 38.3°C 0.91 
Rapidly fatal disease 1.40 
Chills present 0.96 




Table IV. Risk score for predicting bacteraemia* 
Risk score 0 - 2 3 
PI (Bacteraemia absent) 
PI (Bacteraemia present) 
99% 
1% 






Table V. Evaluating an article on diagnostic research"·" 
Is the study valid? 
1. Was there an independent, blind comparison with a 







2. Was the diagnostic test evaluated in an appropriate 
spectrum of patients (such as those in whom it would be 
used in practice)? 
3. Was the reference standard applied regardless of the 
diagnostic test result? (avoiding verification bias) 
4. Were the test's methods described clearly enough to permit 
replication? 
What are the results and their level of precision? 
1. In what form are the results given and how useful are they? 
(sensitivity I specificity, predictive values, likelihood ratios, 
odds ratios) 
2. Are confidence intervals provided around these mean 
estimates? 
Can I use t~ese results in clinical practice? 
1. Will the test be reproducible and well interpreted in my 
practice setting? 
2. Are the results applicable to my patients? 
3. Will the test results change my management? 
4. Will my patients be better off because of the test? 
A number of prediction rules have been developed recently, 
with the Ottawa ankle rule11 ,12 and the Framingham risk 
equation10 among the most quoted. A number of these will be 
developed in future and the diagnostician will have to learn 
how to appraise these rules. One of the fundamental principles 
that needs to be adhered to is that the rule is usually developed 
in one population and validated in another. This is critical in llfJ 
order to make the rule generalisable. Often a diagnostic rule 
works well in the population in which it is developed, but then 
performs poorly when validated. Also important is that for 
logistic regression a large group of patients is usually required, 
at least 10 positive cases for each variable explored (and 
probably more)!'·1' So beware of odds ratios that have been 
derived from a dataset of 50 subjects of whom 10 had the 
disease in question. Further guidelines for the evaluation of 
decision rules are provided in reference 7. 
Rules for interpreting diagnostic literature are given in 
Table V. 1" 15 It is useful to remember that the following 
principles apply to all medical literature: (i) is the study valid?; 
(ii) what are the results and their level of precision?; (iii) can I 
apply these results in my practice? 
Diagnostic research is still in its infancy and the clinician can 
look forward to better ways of overcoming uncertainty 
regarding ruling disease in or out. However, it is imperative 
that the clinician understands and applies the principles related 
to diagnostic research and reasoning in order to ensure optimal 
patient management. 
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PREVALENCE OF PRE-CANCEROUS 
LESIONS AND CERVICAL CANCER 
IN SOUTH AFRICA - A 
MULTICENTRE STUDY 
S Fonn, B Bloch, M Mabina, S Carpenter, H Cronje, C Maise, 
M Bennun, G du Toit, E de Jonge, I Manana, G Lindeque 
Objectives. To describe the age-specific prevalence rates of 
cancer of the cervix in South African women presenting for 
screening. 
Design. A multicentre prevalence survey in 10 geographically 
defined areas following a common core protocol. Services 
were located in existing service sites, witl:l the exception of 
KwaZulu-Natal which used a mobile service. Women aged 20 
years and above were eligible for inclusion. 
Outcome measures. Age-specific cervical cytologically 
diagnosed abnormality rates according to the Bethesda 
classification. 
Results. During the study 20 603 women participated. Eighty 
per cent of the sample had never had a Pap smear before and 
just over 91 % .had not had a Pap smear in the last 5 years. In 
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